Key terms include: $150 million upfront payment to Yao Pharma Up to $1.935 billion in development, regulatory, and commercial milestone payments Tiered royalties on future global sales Coverage across all therapeutic, diagnostic, and prophylactic indications for both human and veterinary use This structure positions the agreement as one of the larger oral-GLP-1 licensing deals in recent years
A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus
Thats why we use body composition scans at our Seattle clinic in South Lake Union
Track 50+ health metrics with AI-powered accuracy
While GLP-1 agonists are generally well-tolerated, there are certain contraindications and precautions to consider, such as: History of pancreatitis, diabetic retinopathy, thyroid cancer